1. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis

   • Guiqiang Wang
   • Atsushi Tanaka
   • Shiv Kumar Sarin

   Guidelines Open access 04 May 2021 Pages: 223 - 257

   

2. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

   • Harshad Devarbhavi
   • Guruprasad Aithal
   • on behalf of the Asia Pacific Association of Study of Liver

   Guidelines 27 February 2021 Pages: 258 - 282

3. Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease

   • Peter L. M. Jansen

   Editorial Open access 01 February 2021 Pages: 283 - 286

   

4. Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma

   • Chien-Wei Su
   • Han-Chieh Lin

   Editorial 13 March 2021 Pages: 287 - 289

5. Chronic hepatitis B: the demise of the ‘inactive carrier’ phase

   • Apostolos Koffas
   • Manoj Kumar
   • S. K. Sarin

   Review Article 27 February 2021 Pages: 290 - 300

   

6. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation

   • Yuan-Hung Kuo
   • Jing-Houng Wang
   • Chien-Hung Chen

   Original Article 04 March 2021 Pages: 301 - 309

   

7. A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir

   • Pao-Yuan Huang
   • Sherry Yueh-Hsia Chiu
   • Tsung-Hui Hu

   Original Article 27 April 2021 Pages: 310 - 317

   

8. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B

   • Menghui Duan
   • Xiaoling Chi
   • Hui Zhuang

   Original Article 26 February 2021 Pages: 318 - 327

   

9. Neonatal hepatitis B vaccination protects mature adults from occult virus infection

   • Ruijun Wang
   • Chang Liu
   • Chunfeng Qu

   Original Article 22 March 2021 Pages: 328 - 337

   

10. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

    • Chen-Hua Liu
    • Po-Yueh Chen
    • Jia-Horng Kao

    Original Article 06 March 2021 Pages: 338 - 349

    

11. Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease

    • Yu Xu
    • Ning Wang
    • Yibin Feng

    Original Article Open access 03 March 2021 Pages: 350 - 365

    

12. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040

    • Takanori Ito
    • Masatoshi Ishigami
    • Mindie H. Nguyen

    Original Article 12 February 2021 Pages: 366 - 379

    

13. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

    • Gabriel Tayguara Silveira Guerreiro
    • Larisse Longo
    • Mário Reis Álvares-da-Silva

    Original Article 10 March 2021 Pages: 380 - 391

14. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice

    • Ryo Yamauchi
    • Hidetoshi Takedatsu
    • Fumihito Hirai

    Original Article 04 January 2021 Pages: 392 - 404

    

15. The metabolic profiles and body composition of lean metabolic associated fatty liver disease

    • Yu-Ming Cheng
    • Jia-Horng Kao
    • Chia-Chi Wang

    Original Article 04 February 2021 Pages: 405 - 412

16. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease

    • Jing-Lu Jin
    • Hui-Wen Zhang
    • Jian-Jun Li

    Original Article 19 March 2021 Pages: 413 - 423

    

17. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study

    • Seong Hee Kang
    • Minjong Lee
    • Soon Koo Baik

    Original Article 16 April 2021 Pages: 424 - 436

    

18. Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan

    • Naruhiro Kimura
    • Masaaki Takamura
    • Shuji Terai

    Original Article 16 April 2021 Pages: 437 - 443

    

19. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma

    • Fei Fan
    • Keji Chen
    • Bin Wu

    Original Article 21 November 2020 Pages: 444 - 458

    

20. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study

    • Lei Liang
    • Bing Quan
    • Tian Yang

    Original Article 03 February 2021 Pages: 459 - 471

    

21. Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma

    • Shang-Chin Huang
    • Sih-Han Liao
    • Jia-Horng Kao

    Original Article 05 February 2021 Pages: 472 - 481

    

22. Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study

    • Young Chang
    • Jeong-Ju Yoo
    • Su Jong Yu

    Original Article 17 February 2021 Pages: 482 - 492

    

23. Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil

    • Fernanda Manhães Pozzobon
    • Hugo Perazzo
    • Maria Chiara Chindamo

    Original Article 03 February 2021 Pages: 493 - 501

    

24. Dynamic Optic Nerve Sheath Diameter (ONSD) guided management of raised intracranial pressure in pediatric acute liver failure

    • Priti Vijay
    • Bikrant Bihari Lal
    • Seema Alam

    Original Article 24 February 2021 Pages: 502 - 509

    

25. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

    • Maaike Biewenga
    • Monique K. van der Kooij
    • Ellen Kapiteijn

    Original Article Open access 25 February 2021 Pages: 510 - 519

    

26. Thromboelastometry in patients with advanced chronic liver disease: a complex interplay

    • Sanchit Sharma

    Letter to the Editor 29 January 2021 Pages: 520 - 521

27. Author’s reply to “Thromboelastometry in patients with advanced chronic liver disease: a complex interplay”

    • Pierre Raeven
    • Mattias Mandorfer
    • Benedikt Simbrunner

    Letter to the Editor 17 February 2021 Pages: 522 - 524

    

28. The prevalence of occult HBV infection in immunized children with HBs Ag positive parents: a hospital based analysis

    • Srinith B. Patil
    • Manoj Kumar Sahu
    • Girish Kumar Pati

    Letter to the Editor 18 February 2021 Pages: 525 - 525

29. C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3

    • Jiong Lin

    Letter to the Editor 10 February 2021 Pages: 526 - 526

30. The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients

    • Chien-Wei Peng
    • Wen-Juei Jeng

    Letter to the Editor 27 April 2021 Pages: 527 - 528

31. Correction to: Targeting the ileal bile salt transporter in the treatment of non‑alcoholic fatty liver disease

    • Peter L. M. Jansen

    Correction 22 April 2021 Pages: 529 - 529